ATE300613T1 - Menschliche, für zyklische nukleotide spezifische phosphodiesterase - Google Patents

Menschliche, für zyklische nukleotide spezifische phosphodiesterase

Info

Publication number
ATE300613T1
ATE300613T1 AT00307981T AT00307981T ATE300613T1 AT E300613 T1 ATE300613 T1 AT E300613T1 AT 00307981 T AT00307981 T AT 00307981T AT 00307981 T AT00307981 T AT 00307981T AT E300613 T1 ATE300613 T1 AT E300613T1
Authority
AT
Austria
Prior art keywords
cyclic nucleotides
human phosphodiesterase
specific
phosphodiesterase specific
amino acid
Prior art date
Application number
AT00307981T
Other languages
English (en)
Inventor
Mark David Fidock
Nicola Melanie Robas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE300613T1 publication Critical patent/ATE300613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00307981T 1999-09-17 2000-09-14 Menschliche, für zyklische nukleotide spezifische phosphodiesterase ATE300613T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922124.4A GB9922124D0 (en) 1999-09-17 1999-09-17 Phosphodiesterase enzymes

Publications (1)

Publication Number Publication Date
ATE300613T1 true ATE300613T1 (de) 2005-08-15

Family

ID=10861181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00307981T ATE300613T1 (de) 1999-09-17 2000-09-14 Menschliche, für zyklische nukleotide spezifische phosphodiesterase

Country Status (7)

Country Link
US (1) US7063971B2 (de)
EP (1) EP1085089B1 (de)
JP (1) JP2001136987A (de)
AT (1) ATE300613T1 (de)
DE (1) DE60021497T2 (de)
ES (1) ES2243208T3 (de)
GB (1) GB9922124D0 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297115A2 (de) * 2000-06-26 2003-04-02 Bayer Aktiengesellschaft Regulation eines menschlichen phosphodiesterase-ähnlichen enzyms
EP1604033A2 (de) * 2002-11-08 2005-12-14 Bayer HealthCare AG Diagnostika und therapeutika für krankheiten, die mit humanen phosphodiesterase 11a3 (pde11a3) assoziiert sind
US7591302B1 (en) * 2003-07-23 2009-09-22 Cooligy Inc. Pump and fan control concepts in a cooling system
US7616444B2 (en) * 2004-06-04 2009-11-10 Cooligy Inc. Gimballed attachment for multiple heat exchangers
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
US20070114010A1 (en) * 2005-11-09 2007-05-24 Girish Upadhya Liquid cooling for backlit displays
EP1989935A4 (de) * 2006-02-16 2012-07-04 Cooligy Inc Flüssigkeitskühlungsschleifen für serveranwendungen
US20070227698A1 (en) * 2006-03-30 2007-10-04 Conway Bruce R Integrated fluid pump and radiator reservoir
TW200809477A (en) 2006-03-30 2008-02-16 Cooligy Inc Integrated fluid pump and radiator reservoir
US20070227709A1 (en) * 2006-03-30 2007-10-04 Girish Upadhya Multi device cooling
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
EP2403873A1 (de) 2009-03-05 2012-01-11 Ablynx N.V. Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
CN118085076A (zh) 2017-06-02 2024-05-28 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
IL270951B2 (en) 2017-06-02 2025-05-01 Merck Patent Gmbh ADAMTS5, MMP13 and aggrecan-binding polypeptides
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
CN110997001A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
US20200392512A1 (en) 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
CN115433733B (zh) 2021-06-04 2025-12-12 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
JP2025523049A (ja) 2022-07-14 2025-07-17 バイオ-テラ ソリュ-ションズ,エルティーディー. 抗Nectin-4抗体及びその使用
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
CN122122303A (zh) 2023-06-22 2026-05-29 阿布林克斯有限公司 用于调节细胞因子受体活性的嵌合蛋白
CN118027196B (zh) 2023-06-25 2025-12-02 合肥天港免疫药物有限公司 抗cd3抗体及其应用
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
KR20260068087A (ko) 2023-09-04 2026-05-13 사노피 글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
KR20250039299A (ko) 2023-09-11 2025-03-20 노보 노르디스크 에이/에스 항-il-6 도메인 항체
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
CN122438859A (zh) 2023-12-22 2026-07-21 阿布林克斯有限公司 用于核内递送的基于蛋白质的缀合载体
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
TW202528354A (zh) 2024-01-03 2025-07-16 中國商北京泰德製藥股份有限公司 B7-h3結合蛋白及其用途
TW202602933A (zh) 2024-03-28 2026-01-16 美商健臻公司 與轉鐵蛋白受體1的特異性表位結合的多肽
CN121005780A (zh) 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 靶向hla-g的抗体或其抗原结合片段及其应用
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0535216T3 (da) * 1991-04-19 2004-02-02 Univ Washington DNA. der koder mammale phosphodiesteraser
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5798246A (en) * 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
EP0967284A1 (de) * 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterasen
US6100037A (en) * 1999-01-07 2000-08-08 Incyte Pharmaceuticals, Inc. Human cyclic nucleotide PDEs

Also Published As

Publication number Publication date
GB9922124D0 (en) 1999-11-17
US20040126863A1 (en) 2004-07-01
DE60021497D1 (de) 2005-09-01
EP1085089A3 (de) 2001-05-09
ES2243208T3 (es) 2005-12-01
US7063971B2 (en) 2006-06-20
DE60021497T2 (de) 2006-05-18
EP1085089B1 (de) 2005-07-27
EP1085089A2 (de) 2001-03-21
JP2001136987A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
DE60021497D1 (de) Menschliche, für zyklische Nukleotide spezifische Phosphodiesterase
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
IL175142A0 (en) High efficiency gene transfer and expresssion in mammalian cells by a multiple transfection procedure of mar sequences
MXPA03002572A (es) Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso.
CY1106041T1 (el) Καινοφανης συλλεκτινη
DE69636495D1 (de) Multi-tumor abweichende wachstumsgene
MXPA03006984A (es) Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma.
NZ508439A (en) Novel endometriosis-associated gene
WO2002097096A3 (en) Nucleotide sequences which code for the metd gene
GB0020331D0 (en) Enzyme
DE60126602D1 (de) Neue collectine
AU2487602A (en) Isolated luciferases and the use thereof
EP0919621A4 (de) Menschliche tak1 und für diese kodierende dna
EA199900893A1 (ru) Бактериальные плазмиды
WO2001029084A3 (en) Novel human proteins and polynucleotides encoding the same
BR0107799A (pt) Proteìna de interação de wt1 wtip
ATE301199T1 (de) Beta-primeverosidase gen
EP1029914A3 (de) Wachstumshormon-reguliertes Wachstumsmarker-Gen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties